Chmielewska L., Krasowska A.: Antybiotyki nie zawsze nasi sprzymierzeńcy. "Aura. Ochrona środowiska"- miesięcznik popularnonaukowy Naczelnej Organizacji Technicznej, Wydawnictwo Czasopism i Książek Technicznych SIGMA-NOT Sp. z o.o. 2001, sierpień, Warszawa.
Janiec W., Krupińska J.: Farmakodynamika. Podręcznik dla studentów farmacji. Wydawnictwo Lekarskie PZWL, Wydanie V unowocześnione. 2002;1004-1008.
Nowicki R.: Farmakoterapia grzybic powierzchniowych: http://www.vita.csc.pl/farmakoterapia.php.
Kaczmarek J., Bocheńska-Marciniak M.: Grzyby i ich udział w chorobach alergicznych. Terapia Alergologia. 2002;119:47-53.
Braham C., Ezzine Sebai N., Arrese J.E., et al.: Il y a sports et spores. Le pied, ses mycoses et onychomycoses. Rev. Med. Liege. 2001;56(11):773-776.
Lacroix C., Baspeyras M., de La Salmoniere P., et al.: Tinea pedis in European marathon runners. JEADV. 2002;16:139-142.
DOI: https://doi.org/10.1046/j.1468-3083.2002.00400.x
Hay R.J., Robles W., Midgley G., et al.: Tinea capitis in Europe: new perspective on an old problem. JEADV. 2001;15:229-233.
DOI: https://doi.org/10.1046/j.1468-3083.2001.00214.x
Rinaldi M.G.: Dermatophytosis: epidemiological and microbiological update. J. Am. Acad. Dermatol. 2000;43(5):120-124.
DOI: https://doi.org/10.1067/mjd.2000.110378
Scheynius A., Johansson C., Buentke E., et al.: Atopic Eczema/Dermatitis Syndrome and Malassezia Int. Arch. Allergy Immunol. 2002;127(3):161-169.
DOI: https://doi.org/10.1159/000053860
Lindborg M., Magnusson C.G.M., Zargari A., et al.: Selective cloning of allergens from the skin colonizing yeast Malassezia furfur by phage surface display technology. J. Invest. Dermatol. 1999;113:156-161.
DOI: https://doi.org/10.1046/j.1523-1747.1999.00661.x
Korting H.C., Schaller M.: Neue Entwicklungen in der medizinischen Mykologie. Hautarzt. 2001;52:91-97.
DOI: https://doi.org/10.1007/s001050051271
Adamski Z., Deja M.: Nowości i przyszłość w terapii przeciwgrzybiczej. Mikol. Lek. 2005;12(2):115-121.
Aoki Y., Yamamoto M., Hosseini-Mazinani S.M., Koshikawa, N. Sugimoto K., Arisawa M.: Antimicrob. Agents Chemother. 1996;40:127-132.
DOI: https://doi.org/10.1128/AAC.40.1.127
Pfaller M.A., et al.: Comparison of visual and spectrophotometric methods for MIC endpoint determinations by using broth microdilution methods to test five antifungal agents including the new triazole DoSyo: Clin. Mikrobiol. 1995;533:1094-1097.
DOI: https://doi.org/10.1128/jcm.33.5.1094-1097.1995
Pfaller M.A., et al.: International surveillance of bloodstream infections due to Candida species in the European SENTRY programe: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbol. Infect. Dis. 1999;35:19-25.
DOI: https://doi.org/10.1016/S0732-8893(99)00046-2
Marco F., et al.: Activity of Mk-0991 (L-743,872) a new echinocandin compared with those of LY303366 and four other antifungal agents tested against bloodstream isolates of Candida sp. Diagn. Microbiol. Infect. Dis. 1998;32:33-37.
DOI: https://doi.org/10.1016/S0732-8893(98)00050-9
Didomenico B.: Novel antifungal drugs. Curr. Opin. Microb. 1999;2:509-515.
DOI: https://doi.org/10.1016/S1369-5274(99)00009-0
Hryncewicz-Gwóźdź A., Plomer-Niezgoda E., Baran W.: Perspektywy terapii przeciwgrzybiczej. Mikol. Lek. 2003;10:207-211.
DeWet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., Diekmann-Berndt H.: A randomized, double-blind, parallel - group, dose-response study of micafungin compared with fluconazole for treatment of esophagea candidiasis in HIV-positive patients. Clin. Infect. Dis. 2004;15:842-849.
DOI: https://doi.org/10.1086/423377
Polak A.: Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy. 1978;24(1):2-16.
DOI: https://doi.org/10.1159/000237753
Vermes A., et al.: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000;46:171-9.
DOI: https://doi.org/10.1093/jac/46.2.171
Zejc A., Gorczyca M.: Chemia leków. Wydawnictwo Lekarskie PZWL, Wydanie II zmienione. 2002;700-703.
Gupta A.K., Skinner A.R.: Ciclopirox for the treatment of superficial fungal infections: a review. Int. J. Dermatol. 2003;42(1):3-9.
DOI: https://doi.org/10.1046/j.1365-4362.42.s1.2.x
Lee J.H., Lee H.S., Eun H.C., et al: Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. J. Dermatol. Treat. 2003;14:212-215.
DOI: https://doi.org/10.1080/714070652
Sterling T.R., Gasser R.A. Jr , Ziegler A.: Emergence of resistance to amphotericin B during therapy for candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. 1996;23:187-188.
DOI: https://doi.org/10.1093/clinids/23.1.187
Walsh T.J., Finberg R.W., Arndt C., et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999;340:764-771.
DOI: https://doi.org/10.1056/NEJM199903113401004
Prajna N.V., Nirmalan P.K., Mahalakshmi R., Lalitha P., Srinivasan M.: Concurrent use of 5% natamycin and 2% econazole for the management of fungal keratitis. Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India. Cornea. 2004; 23(8):793-6.
DOI: https://doi.org/10.1097/01.ico.0000134193.64357.82
Millns B., Martin M.V.: Nystatin pastilles and suspension in the treatment of oral candidosis. Br. Dent. J. 1996;181:209-11.
DOI: https://doi.org/10.1038/sj.bdj.4809214
Gøtzsche P.C., Johansen H.K.: Nystatin prophylaxis and treatment in severely immunodepressed patients. Available in The Cochrane Library; Issue 2. Chichester: Wiley J.: 2004.
Komori T.: Trichomycin B, a polyene macrolide from Streptomyces. Research and Technology Group, Fujisawa Pharmaceutical Co., Ltd., Japan. J. Antibiot. 1990;43(7): 778-82.
DOI: https://doi.org/10.7164/antibiotics.43.778
Norgaard O.: Pecilocin allergy. Hautarzt. 1977;28(1):35-6.
O'Sullivan D.P.: Terbinafine: tolerability in general medical practice. Br. J. Dermatol. 1999;141(56):21-5.
DOI: https://doi.org/10.1046/j.1365-2133.1999.00010.x
Fuller L.C., et al.: A randomized comparison of 4 weeks of terbinafine vs 8 weeks of griseofulvin for the treatment of tinea capitis. Br. J. Dermatol. 2001;144:321-7.
DOI: https://doi.org/10.1046/j.1365-2133.2001.04022.x
Ablon G., Rosen T., Spedale J.: Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Department of Dermatology, Baylor College of Medicine, USA. Int. J. Dermatol. 1996;35(8):591-3.
DOI: https://doi.org/10.1111/j.1365-4362.1996.tb03668.x
Haria M., Bryson H.M.: Amorolfine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs. 1995;49:103-20.
DOI: https://doi.org/10.2165/00003495-199549010-00008
Alchorne M.M., Paschoalick R.C., Forjaz M.H.: Comparative study of tioconazole and clotrimazole in the treatment of tinea versicolor. Clin. Ther. 1987;9:360-367.
Jones R.N., Bale M.J., Hoban D., et al: In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (Vagistat-1 6.5%) application. Diagn. Microbiol. Infect. Dis. 1993;17:45-51.
DOI: https://doi.org/10.1016/0732-8893(93)90069-J
Carrillo-Munoz A.J., Tur-Tur C., Bornay-Llinares F.J., et al: Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 1999;11(3):187-190.
Dellenbach P., Thomas J.L., Guerin V., et al: Topical treatment of vaginal candidosis with sertaconazole and econazole sustained-release suppositories. Int. J. Gynecol. Obstet. 2000;71:47-52.
DOI: https://doi.org/10.1016/S0020-7292(00)00348-9
Prajna N.V., John R.K., Nirmalan P.K., et al: A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br. J. Ophthalmol. 2003: 87:1235-1237.
Van Esso D., Fajo G., Losada I., et al: Sertaconazole in the treatment of pediatric patients with cutaneous dermatophyte infections. Clin. Ther. 1995;17:264-269.
DOI: https://doi.org/10.1016/0149-2918(95)80024-7
Prajna N.V., John R.K., Nirmalan P.K., et al.: A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br. J. Ophthalmol. 2003;87:1235-1237.
DOI: https://doi.org/10.1136/bjo.87.10.1235
Fontana C., Cammarata E., Greco M., et al: In vitro activity of fenticonazole on trichomonas vaginalis and gardnerella vaginalis. Curr. Ther. Res. 1990; 48:44-51.
Fioroni A., Terragni L., Vannini P., et al: Fenticonazole plasma levels during treatment with fenticonazole 2% cream and spray in patients with dermatomycoses. Curr. Ther. Res. 1990;47:997-1003.
Gugnani H.C., Akpata L.E., Gugnani M.K., et al: Isoconazole nitrate in the treatment of tropical dermatomycoses. Mycoses. 1994;37(1-2):39-41.
DOI: https://doi.org/10.1111/j.1439-0507.1994.tb00283.x
Lazarov A., Ingber A.: Pustular allergic contact dermatitis to isoconazole nitrate. Am. J. Contact. Derm. 1997;8(4):229-230.
DOI: https://doi.org/10.1097/01206501-199712000-00008
Stevens R.E., Konsil J., Verrill S.S., et al: Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J. Clin. Pharmacol. 2002;42:52-60.
DOI: https://doi.org/10.1177/0091270002042001006
Fernandez L., Maquiera E., Rodriguez F., et al: Systemic contact dermatitis from miconazole. Contact Dermatitis. 1996;34:217.
DOI: https://doi.org/10.1111/j.1600-0536.1996.tb02178.x
Tsunoda S.M., Velez R.L., von Moltke L.L., et al: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther. 1999;66:461-471.
DOI: https://doi.org/10.1016/S0009-9236(99)70009-3
Cuce L.C.: Sulconazole nitrate 1% cream vs clotrimazole 1% cream in the treatment of tinea pedis. Curr. Ther. Res. 1989;45:421-427.
Hajman A.J.: Vulvovaginal candidosis: comparison of 3-day treatment with 2% butoconazole nitrate cream and 6-day treatment with 1% clotrimazole cream. J. Int. Med. Res. 1988;16:367-375.
DOI: https://doi.org/10.1177/030006058801600506
Brown D., Henzl M.R., Kaufman R.H. and the Gynazole 1 Study Group.: Butoconazole nitrate 2% for vulvovaginal candidiasis; new, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. J. Reprod. Med. 1999;44:933-938.
Kohl T.D., Martin D.C., Berger M.S.: Comparison of topical and oral treatments for tinea gladiatorum. Clin. J. Sport. Med. 1999; 9(3):161-166.
DOI: https://doi.org/10.1097/00042752-199907000-00008
Mselle J.: Use of topical clotrimazole in human keratomycosis. Ophthalmologica. 2001; 215:357-360.
DOI: https://doi.org/10.1159/000050885
Woolley P.D., Higgins S.P.: Comparison of clotrimazole, fluconazole and itraconazole in vaginal candidiasis. Brit. J. Clin. Pract. 1995;49:65-66.
Plomer-Niezgoda E., Baran E.: Flutrimazol - ocena właściwości farmakologicznych i klinicznych. Mikol. Lek. 2002;9(1):41-44.
Bartroli J., Alquero M., Boncompte E., Forn J.: Synthesis and antifungal activity of series of difluorotritylimizoles. Arzneim.-Forsch./Drug Res. 1992;42:832-855.
Beierdoerffer H: Erfahrungen mit Croconazol in der dermatologischen Praxis. Der Deutsche Dermatologe. 1993;12:1.
Meinicke K., Michel G.: Croconazole: a new broad-spectrum agent in the treatment of fungal skin infections. Int. J. Clin. Pharmacol. Res. 1994;14:139-148.
Amichai B.: Treatment of pityriasis versicolor with a shampoo containing 1% bifonazole (Agispor® shampoo) in children. Clin. Exp. Dermatol. 2000;26:655-660.
DOI: https://doi.org/10.1046/j.1365-2230.2000.00730-6.x
Carrillo-Munoz A.J., Tur-Tur C., Bornay-Llinares F.J., et al.: Comparative study of the in vitro antifungal activity of bifonazole, naftifine and sertaconazole against yeasts. J. Chemother. 1999;11(3):187-190.
DOI: https://doi.org/10.1179/joc.1999.11.3.187
Gugnani H.C., Ideyi C., Gugnani M.K.: Oxiconazole in the treatment of tropical dermatomycoses. Curr. Ther. Res. 1993;54:122-125.
DOI: https://doi.org/10.1016/S0011-393X(05)80625-3
Pariser D.M., Pariser R.J.: Oxiconazole nitrate lotion, 1 percent: an effective treatment for tinea pedis. Cutis. 1994;54:43-44.
Bulkowstein M., Mordish Y., Zimmerman D.R. et al: Ketoconazole-induced neurologic sequelae. Vet. Hum. Toxicol. 2003;45(5):239-240.
Millikan R., Baez L., Banergee T., et al.: Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer. Urologic Oncology. 2001;6:111-115.
DOI: https://doi.org/10.1016/S1078-1439(00)00123-X
Moody D.E., Walsh S.L., Rollins D.E., et al: Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin. Pharmacol. Ther. 2004;76(2):154-166.
DOI: https://doi.org/10.1016/j.clpt.2004.04.004
Unholzer A., Schinzel S., Nietsch K.H., et al: Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis. A double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin. Drug. Invest. 2002;22(3):167-172.
DOI: https://doi.org/10.2165/00044011-200222030-00003
Muijsers R.B.R., et al.: Voriconazole: in the treatment of invasive aspergillosis. Drugs. 2002;62:2655-64.
DOI: https://doi.org/10.2165/00003495-200262180-00010
Pearson M.M., et al.: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. 2003;37:420-32.
DOI: https://doi.org/10.1345/aph.1C261
Pappas P.G., et al.: Alopecia associated with fluconazole therapy. Ann. Intern. Med. 1995; 123:354-7.
DOI: https://doi.org/10.7326/0003-4819-123-5-199509010-00006
Bronstein J.A., et al.: Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin. Infect. Dis. 1997;25:1266-7.
DOI: https://doi.org/10.1086/516975
Takahashi T., et al.: Desensitization to fluconazole in an AIDS patient. Ann. Pharmacother. 2001;35:642-3.
DOI: https://doi.org/10.1345/aph.10285
Fung-Tomc J.C., Huczko E., Minassian B., Bonner D.P.: In vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 1998;42:313-318.
DOI: https://doi.org/10.1128/AAC.42.2.313
Sheehan D.J., Hitchcock C.A., Sibley C.M.: Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 1999;12:40-79.
DOI: https://doi.org/10.1128/CMR.12.1.40
Meletiadis J., et al.: In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob. Agents Chemother. 2000;44:470-2.
DOI: https://doi.org/10.1128/AAC.44.2.470-472.2000
Goldman M., et al.: Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob. Agents Chemother. 2000;44:1585-7.
DOI: https://doi.org/10.1128/AAC.44.6.1585-1587.2000
Dannaoui E., et al.: Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 2001;47:333-340.
DOI: https://doi.org/10.1093/jac/47.3.333
Garcia F.R.G., Sauceda L., Ramirez P.D., Cruz T.F., Romero C.R.: Effectiveness and safety of ciclopirox olamine 1% vaginal cream versus terconazole 0.8% vaginal cream in the treatment of genital candidiasis. Ginecol. Obstet. Mex. 2000;68:154-9.
Courtney R., Pai S., Laughlin M., et al.: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 2003;47:2788-2795.
DOI: https://doi.org/10.1128/AAC.47.9.2788-2795.2003
Courtney R., Radwanski E., Lim J., et al: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 2004;48:804-808.
DOI: https://doi.org/10.1128/AAC.48.3.804-808.2004
Herbrecht R.: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. 2004;58(6):612-624.
DOI: https://doi.org/10.1111/j.1368-5031.2004.00167.x
Segal B.H. et al.: Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin. Infect. Dis. 2005;40:1684-8.
DOI: https://doi.org/10.1086/430068
Carrillo-Munoz A.J., Quindos G., Lopez-Ribot J.L.: Current Developments in Anti-Fungal Agents. Current Medicinal Chemistry - Anti-Infective Agents. 2004;3(27):297-323.
DOI: https://doi.org/10.2174/1568012043353766
Sorbera, L.A., Bartroli, J., Castaner, J.: In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother. 2004;48(2):384-7.
DOI: https://doi.org/10.1128/AAC.48.2.384-387.2004
Benfield P. Clissold S.P.: Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial dermatomycoses. Drugs. 1988;35:143-153.
DOI: https://doi.org/10.2165/00003495-198835020-00004
English
Język Polski
